Bio Ray Biotech

Bio-Ray Biotech is a leading Chinese biopharmaceutical company specializing in the end-to-end development, large-scale manufacturing, and commercialization of innovative antibody drugs and biosimilars. Originally established as the biologics division of Hisun Pharmaceutical, the company became an independent entity in 2019 following a landmark investment by PAG. Bio-Ray's commercial portfolio features several high-impact biosimilars targeting autoimmune diseases and oncology, including etanercept, adalimumab, and infliximab. The company maintains a robust R&D pipeline focused on next-generation biologics such as bispecific antibodies and antibody-drug conjugates (ADCs). With integrated facilities across Taizhou, Hangzhou, and Shanghai, Bio-Ray leverages significant mammalian cell culture capacity to serve both domestic and international markets.